The approval came days before the FDA’s expected deadline and makes this the only PD-1 inhibitor approved for resectable ...

Opdivo (nivolumab) for resectable non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) ...

The checkpoint inhibitor is now approved, based on CheckMate 77T findings, for neoadjuvant/adjuvant use in patients with ...

The FDA has approved nivolumab plus chemotherapy as a neoadjuvant treatment for operable stage IIA to IIIB non–small cell ...

In 2023, BMS received a similar approval across the pond. The National Institute for Health and Care Excellence (NICE) ...

The FDA has approved Opdivo (nivolumab) as neoadjuvant and adjuvant treatment for adults with resectable NSCLC.

Patients with muscle-invasive bladder cancer experienced safe medical and surgical treatment with the NURE-combo.

The approval was based on data from the randomized, double-blind, placebo-controlled, phase 3 CheckMate -77T trial.

Bristol Myers Squibb has received FDA approval for Opdivo (nivolumab) combined with chemotherapy as a perioperative treatment ...

The Food and Drug Administration has approved Opdivo before and after surgery for some with non-small cell lung cancer.

Toni Choueiri, MD, discusses the rationale behind the drug combination of tivozanib and nivolumab in the TiNivo-2 study.

BriaCell Therapeutics announced that its Bria-IMT cell therapy, plus an immune checkpoint inhibitor regimen, achieved ...